02208nam 2200361Ia 450 99639404640331620200824121648.0(CKB)4940000000114690(EEBO)2240915172(UnM)99895891e(UnM)99895891(EXLCZ)99494000000011469019980925d1686 uy |engurbn||||a|bb|[Christ crucified: or, The marrow of the Gospel[electronic resource] evidently holden forth in LXXII sermons, on the whole 53. chapter of Isaiah. Wherein the text is clearly and judiciously opened up, and a great many most apposite, profoundly spiritual and very edifying points of doctrine in a dilectable variety drawen from it; with choice and excellent practical improvements made of them. Wherein also several adversaries of the truth, as Socinians, papists, arminians and Antinomians, are smartly, solidly and succinctly reasoned with and refuted. Wherein, moreover many errours in practice incident to professours otherwise sound and orthodox in their opinions are discovered; and not a few grave, deep, and very concerning cases of conscience, soberly and satisfyingly discussed. By that able minister of the New Testament Mr. James Durham, sometime minister of the gospel at Glasgow, and solemnly called to a publick profession of divinity in the University there, and also His Maiesties Chaplain in Ordinary when he was in Scotland.]The second edition.Edinburgh printed by the heir of Andrew Anderson, printer to the Kings most sacred Majestyanno Dom. 1686[61], 47-466 pEdition statement from Wing CD-ROM, 1996.Oe copy severely damaged affecting text up to Sig. F.Reproduction of original in the Exeter College Library, Oxford, England.eebo-0051Sermons, English17th centurySermons, EnglishDurham James1622-1658.896300Cu-RivESCu-RivESWaOLNBOOK996394046403316Christ crucified: or, The marrow of the Gospel2307771UNISA02941oam 2200457 450 991013640760332120230621135800.09782889193325 (ebook)(CKB)3710000000612036(oapen)https://directory.doabooks.org/handle/20.500.12854/45512(EXLCZ)99371000000061203620191103c2014uuuu uu |engurmn|---annantxtrdacontentcrdamediacrrdacarrierDrug-diagnostics co-development in oncology[electronic resource] /topic editor Jan Trøst JørgensenFrontiers Media SA2014France :Frontiers Media SA,20141 online resource (111 pages) colour illustrations, chartsFrontiers Research TopicsIncludes bibliographical references.The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs.OncologyIHCfishprecision medicineNGSDrug-diagnostic co-developmentcompanion diagnosticsoncologypersonalized medicineOncology.615.1/9Jan Trost Jorgensenauth1367185Jørgensen Jan TrøstUkMaJRU9910136407603321Drug-diagnostics co-development in oncology3389914UNINA